San Antonio Breast Cancer Symposium | Conference

RSClin Delivers More Precise Assessment of Distant Recurrence Risk and Chemo Benefit in Early Breast Cancer

December 11th 2020

The clinical tool RSClin™, which integrates the 21-gene expression assay and clinical pathologic features, was shown to provide more prognostic information than the 21-gene recurrence score or clinical pathologic features alone and a more precise prediction of absolute chemotherapy benefit in node-negative early breast cancer.

GI AEs Associated With Oral Paclitaxel Plus Encequidar Subside with Antiemetics, Loperamide in Metastatic Breast Cancer

December 11th 2020

December 11, 2020 - Gastrointestinal adverse events that occurred in patients with metastatic breast cancer who were treated with oral paclitaxel and encequidar can be managed by the use of 5- HT3 inhibitors and early intervention with loperamide.

Sacituzumab Govitecan Improves PFS in Metastatic TNBC With Brain Metastases

December 11th 2020

December 11, 2020 - Sacituzumab govitecan increased response rates and improved progression-free survival vs chemotherapy in patients with metastatic triple-negative breast cancer with stable brain metastases, although no overall survival improvement was observed.

ctDNA Emerges as a Biomarker for Response, Outcomes in High-Risk Early Breast Cancer

December 11th 2020

December 11, 2020 - The presence of circulating tumor DNA following neoadjuvant chemotherapy with or without pembrolizumab was a biomarker for response and distant recurrence-free survival in patients with high-risk early-stage breast cancer.

Combination Therapy with Tesetaxel and Capecitabine Improves PFS in HER2-, HR+ Metastatic Breast Cancer

December 11th 2020

December 11, 2020 - Patients with human epidermal growth factor receptor 2-negative, hormone receptor-positive metastatic breast cancer who were treated with tesetaxel and a reduced dose of capecitabine experienced improvements in progression-free survival compared with those treated with the FDA-approved dose of capecitabine alone.

Plinabulin/Pegfilgrastim Shows 53% Efficacy Rate in Preventing Profound Neutropenia

December 11th 2020

December 11, 2020 - The combination of plinabulin and pegfilgrastim was 53% more effective in reducing the incidence of profound neutropenia compared with pegfilgrastim alone in patients undergoing chemotherapy, according to full findings of the phase 3 PROTECTIVE-2 trial.

AI-Based Analysis Enhances Prediction of Best Responders for Trastuzumab Deruxtecan

December 11th 2020

December 11, 2020 - Use of a novel HER2 quantitative continuous score was better able to provide an objective and quantitative assessment of HER2 expression to identify patients who are most likely to respond to fam-trastuzumab deruxtecan-nxki.

GP2/GM-CSF Combo Elicits 100% DFS Rate in HER2 3+ Breast Cancer at 5 Years

December 11th 2020

December 10, 2020 - The GP2 immunotherapy plus granulocyte-macrophage colony-stimulating factor demonstrated potent responses and a 100% disease-free survival in patients with HER2/neu 3–positive disease who received adjuvant trastuzumab.

Amcenestrant Demonstrates Intriguing Activity in Postmenopausal Advanced ER+ Breast Cancer

December 11th 2020

December 10, 2020 - Amcenestrant elicited antitumor activity in heavily pretreated, postmenopausal women with advanced or metastatic estrogen receptor–positive breast cancer.

Neoadjuvant Atezolizumab/Chemo Improves Outcomes Without Impacting Day-to-Day Function or HRQoL in Early TNBC

December 10th 2020

December 10, 2020 - The addition of neoadjuvant atezolizumab to nab-paclitaxel followed by doxorubicin plus cyclophosphamide was found to improve pathologic complete responses compared with placebo plus chemotherapy in patients with early triple-negative breast cancer without adding additional treatment burden to patients.

Dr. Tolaney on the Safety Profile of SAR439859 in ER+/HER2- Metastatic Breast Cancer

December 10th 2020

Sara M. Tolaney, MD, MPH, discusses the safety profile of SAR439859 in estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr. Tripathy on Updated Results of the MONALEESA-7 Trial in HR+/HER2- Breast Cancer

December 10th 2020

Debu Tripathy, MD, discusses updated results of the phase 3 MONALEESA-7 trial in hormone receptor–positive, HER2-negative breast cancer.

Sacituzumab Govitecan Induces Clinical Benefit in Metastatic TNBC, Irrespective of Trop-2 Expression

December 10th 2020

December 10, 2020 - The antibody-drug conjugate sacituzumab govitecan was found to induce clinical benefit over physician’s choice of therapy in patients with metastatic triple-negative breast cancer, irrespective of Trop-2 expression; however, greater efficacy was observed in those who had a medium or high Trop-2 score.

Efficacy Analysis for Frontline Combination Therapy With Pembrolizumab Indicates Benefit in TNBC, Regardless of Chemotherapy Choice

December 10th 2020

December 10, 2020 - Frontline pembrolizumab plus chemotherapy for advanced triple-negative breast cancer demonstrated efficacy across key patient subgroups, including those with PD-L1 expression by combined positive score.

Ipatasertib/Paclitaxel Fails to Improve PFS in PIK3CA/AKT1/PTEN-Altered TNBC

December 10th 2020

December 10, 2020 — The combination of ipatasertib and paclitaxel failed to show a significant improvement in progression-free survival vs placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered locally advanced, unresectable or metastatic triple-negative breast cancer.

CTC Count Possible Biomarker for Using HER2-Directed Therapy in MBC

December 10th 2020

December 10, 2020 - Favorable outcomes after treatment with the HER2-directed lapatinib were indicated by early declines in circulating tumor cell counts in patients with metastatic breast cancer who initially had HER2-negative primary tumors but positive HER2 CTCs.

Neratinib Leads to Fewer Deaths, CNS Benefit, Potential OS Improvement in Early-Stage HER2+ Breast Cancer

December 10th 2020

December 10, 2020 - At 8 years of follow up, fewer deaths and improved cumulative incidence of central nervous system recurrences were reported with adjuvant neratinib compared with placebo in patients with early-stage HER2-positive breast cancer after trastuzumab-based therapy, according to updated results of the phase 3 ExteNET trial.

Alpelisib/Letrozole Retains Efficacy in PIK3CA-Mutant HR+ Advanced Breast Cancer Post-CDK4/6 Inhibition/Fulvestrant

December 10th 2020

The combination of alpelisib and letrozole sustained efficacy and did not result in any new safety signals in patients with PIK3CA-mutant hormone receptor–positive, HER2-negative advanced breast cancer who received prior treatment with the combination of a CDK4/6 inhibitor and fulvestrant.

Pregnancy May Be Difficult for Breast Cancer Survivors, But Often Produces Healthy Babies with No Impact on Long-Term Survival

December 10th 2020

December 10, 2020 - Women who survive breast cancer may have more difficulty in becoming pregnant when compared to the general population, and have a risk of preterm labor, but most deliver healthy babies and experience no detrimental effects on their long-term survival.

Oral Paclitaxel-Encequidar Elicits Responses in Radiation-Associated Breast Angiosarcoma

December 10th 2020

December 10, 2020 - Oral paclitaxel in combination with encequidar may provide patients with radiation-associated breast angiosarcoma an effective treatment.